2021
Female sex as an independent predictor of high bleeding risk among East Asian percutaneous coronary intervention patients: A sex difference analysis
Kodaira M, Sawano M, Tanaka M, Kuno T, Numasawa Y, Ueda I, Fukuda K, Kohsaka S. Female sex as an independent predictor of high bleeding risk among East Asian percutaneous coronary intervention patients: A sex difference analysis. Journal Of Cardiology 2021, 78: 431-438. PMID: 34172350, DOI: 10.1016/j.jjcc.2021.05.016.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionAcute coronary syndromeFine-Gray modelPrimary outcomeFemale sexPercutaneous coronary intervention patientsLower body mass indexEtiology of readmissionMulticenter PCI registryPrevious heart failureUnadjusted readmission ratesAdjusted hazard ratioHigh bleeding riskBody mass indexLong-term outcomesCox regression modelACS survivorsCumulative incidence functionMajor bleedingMore comorbiditiesBleeding riskCoronary syndromeIntervention patientsPCI registryCoronary intervention
2018
First‐in‐human experience with Aortix intraaortic pump
Vora A, Jones W, DeVore A, Ebner A, Clifton W, Patel M. First‐in‐human experience with Aortix intraaortic pump. Catheterization And Cardiovascular Interventions 2018, 93: 428-433. PMID: 30311400, PMCID: PMC6586004, DOI: 10.1002/ccd.27857.Peer-Reviewed Original ResearchMeSH KeywordsAgedAortaCoronary Artery DiseaseCoronary CirculationDevice RemovalFeasibility StudiesFemaleGlomerular Filtration RateHeart-Assist DevicesHemodynamicsHumansKidneyKidney DiseasesMaleMiddle AgedParaguayPercutaneous Coronary InterventionProspective StudiesProsthesis DesignProsthesis ImplantationRecovery of FunctionRegional Blood FlowRenal CirculationRisk FactorsTime FactorsTreatment OutcomeUrinationVentricular Dysfunction, LeftVentricular Function, LeftConceptsPercutaneous mechanical circulatory supportHigh-risk PCIRenal dysfunctionVentricular functionAdverse eventsImpaired left ventricular functionFirst-in-human experienceSignificant hemolysisPercutaneous mechanical circulatory support devicesSingle-center studyClinically significant hemolysisLeft ventricular functionPercutaneous coronary intervention patientsHigh-risk percutaneous coronary interventionRenal protective effectsPotential renal protective effectsVascular access complicationsPercutaneous coronary interventionMechanical circulatory supportComplex coronary diseaseVascular closure deviceEstimated GFRUrine outputHemodynamic compromiseSystemic perfusion
2017
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Cavallari L, Lee C, Beitelshees A, Cooper-DeHoff R, Duarte J, Voora D, Kimmel S, McDonough C, Gong Y, Dave C, Pratt V, Alestock T, Anderson R, Alsip J, Ardati A, Brott B, Brown L, Chumnumwat S, Clare-Salzler M, Coons J, Denny J, Dillon C, Elsey A, Hamadeh I, Harada S, Hillegass W, Hines L, Horenstein R, Howell L, Jeng L, Kelemen M, Lee Y, Magvanjav O, Montasser M, Nelson D, Nutescu E, Nwaba D, Pakyz R, Palmer K, Peterson J, Pollin T, Quinn A, Robinson S, Schub J, Skaar T, Smith D, Sriramoju V, Starostik P, Stys T, Stevenson J, Varunok N, Vesely M, Wake D, Weck K, Weitzel K, Wilke R, Willig J, Zhao R, Kreutz R, Stouffer G, Empey P, Limdi N, Shuldiner A, Winterstein A, Johnson J, Network I. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovascular Interventions 2017, 11: 181-191. PMID: 29102571, PMCID: PMC5775044, DOI: 10.1016/j.jcin.2017.07.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedClinical Decision-MakingClopidogrelCytochrome P-450 CYP2C19Drug ResistanceFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPharmacogeneticsPharmacogenomic TestingPharmacogenomic VariantsPlatelet Aggregation InhibitorsPrasugrel HydrochloridePredictive Value of TestsRisk AssessmentRisk FactorsTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsGenotype-guided antiplatelet therapyCYP2C19 genotype-guided antiplatelet therapyCYP2C19 loss-of-function allelesLoss-of-function allele carriersPercutaneous coronary interventionAdverse cardiovascular eventsAntiplatelet therapyCardiovascular eventsAlternative therapiesRandomized studyLoss-of-function allelesAllele carriersCoronary interventionClinical implementationMonths of percutaneous coronary interventionInverse probability of treatment weightingInverse probabilityPercutaneous coronary intervention patientsProbability of treatment weightingAcute coronary syndromeAlternative antiplatelet therapyClopidogrel effectCoronary syndromeCox regressionClinical genotyping
2014
INTEGRATING NATIONAL CARDIOVASCULAR DATA REGISTRY (NCDR®) INFORMATION INTO THE CARE OF PERCUTANEOUS CORONARY INTERVENTION PATIENTS: A QUALITATIVE PERSPECTIVE
Minges K, Chen P, Cherlin E, Rumsfeld J, Messenger J, Hermann T, Elma M, Curtis J. INTEGRATING NATIONAL CARDIOVASCULAR DATA REGISTRY (NCDR®) INFORMATION INTO THE CARE OF PERCUTANEOUS CORONARY INTERVENTION PATIENTS: A QUALITATIVE PERSPECTIVE. Journal Of The American College Of Cardiology 2014, 63: a1573. DOI: 10.1016/s0735-1097(14)61576-x.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply